Dr. rer.nat.


1996 – 2000   PhD position, Max-Planck Institute Bad Nauheim, Germany, Kerckhoff Clinic and Kerckhoff Institute, Prof. Dr. W. Risau, PD Dr. M. Clauss
2000 – 2002  Postdoc researcher, Max-Planck Institute, Kerckhoff Institute, Bad Nauheim, Germany, PD Dr. M. Clauss
2002 – 2004 Research Scientist, Artemis Pharmaceuticals GmbH, Cologne, Germany
2004 – 2006 Research Scientist, Evotec Neurosciences AG, Zurich, Switzerland
2006 – 2011 Research Scientist, Evotec AG, In vivo Pharmacology, Hamburg, Germany
2011 – present                          Junior Group Leader Preclinical Imaging, Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4, Director Prof. N.J. Shah)


Academic Qualification and Education

1995     Diploma in Biology, Technische Universität Darmstadt, Germany
2000 Doctor of natural sciences, Technische Universität Darmstadt, Germany


Other Appointments

  • Director of Preclinical Research & Founder of Priavoid GmbH, Jülich, Germany (2017)
  • Deputy of Animal Facility at Research Centre Jülich (2017 – present)
  • Member of the Committee for animal protection at Research Centre Jülich (2016 – present)
  • Radiation Protection Officer, Research Centre Jülich (2014 - present)
  • Biosafety Officer (Project Leader for work with genetically modified organisms, §§ 14-15 GenTSV) at Research Centre Jülich (2011 - present)
  • Biosafety Officer, Evotec Neurosciences, Zurich (2004 - 2006)
  • Associated Editor of the Journal of Alzheimer´s Disease (2019)
  • Reviewer for different international scientific journals
  • Member of the Society of Neuroscience (since 2019)
  • Member of the Nuclear Medicine Association of Northrhine-Westphalia (since 2016)
  • Member of the German Life Science Association (since 2011)


Research Topics

  • Analysis of neurodegeneration in several rodent models of CNS diseases
  • Preclinical positron emission tomography (PET) and magnet resonance imaging (MRI) of CNS lesions, neurodegeneration and neuroinflammation
  • Monitoring of preclinical therapeutic studies with PET, MRI and behavioural tests


Key Publications

  1. Schemmert S, Schartmann E, Honold D, Zafiu C, Ziehm T, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D (2019). „Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.“ Neurobiol Dis. 2019 Apr;124:36-45.
  2. Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D (2018). “Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.“ Mol Neurobiol. 2019 Mar;56(3):2211-2223.
  3. Schartmann E, Schemmert S, Niemietz N, Honold D, Ziehm T, Tusche M, Elfgen A, Gering I, Brener O, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A (2018). „In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease.“ J Alzheimers Dis. 2018;64(3):859-873.
  4. Dunkelmann T, Schemmert S, Honold D, Teichmann K, Butzküven E, Demuth HU, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A (2018). „Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice.“ J Alzheimers Dis. 2018;63(1):115-130.
  5. Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Joni Shah N, Langen KJ, Kutzsche J, Willbold D, Willuweit A (2018). „Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.“ Eur J Pharm Sci. 2018 Mar 1;114:93-102.
  6. Jiang, N., D. Frenzel, E. Schartmann, T. van Groen, I. Kadish, N.J. Shah, K.J. Langen, D. Willbold, A.Willuweit (2016). „Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide.“ Biochim Biophys Acta. 1858(11):2717-2724.
  7. Jiang, N., L.E. Leithold, J. Post, T. Ziehm, J. Mauler, L. Gremer, M. Cremer, E. Schartmann, N.J. Shah, J. Kutzsche, K.J. Langen, J. Breitkreutz, D. Willbold, A.Willuweit(2015). “Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease.“ PLoS One. 10(6):e0128553.
  8. Geisler,  S., A. Willuweit, M. Schroeter, K. Zilles, K. Hamacher, N. Galldiks, N.J. Shah, H.H. Coenen, K.J. Langen (2013). „Detection of remote neuronal reactions in the Thalamus and Hippocampus induced by rat glioma using the PET tracer cis-4-[¹⁸F]fluoro-D-proline”. J Cereb Blood Flow Metab. 33(5):724-31.
  9. Manook, A., B.H. Yousefi, A. Willuweit, S. Platzer, S. Reder, A. Voss, M. Huisman, M. Settles, F. Neff, J. Velden, M. Schoor, H. von der Kammer, H.J. Wester, M.Schwaiger, G. Henriksen, A. Drzezga (2012). „Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease”. PLoS One. 7(3):e31310.
  10. Willuweit, A., J. Velden, R. Godemann, A. Manook, F. Jetzek, H. Tintrup, G. Kauselmann, B. Zevnik, A. Drzezga, G. Henriksen, J. Pohlner, M. Schoor, J. Kemp, H. v.d. Kammer (2009). “Early-Onset and Robust Amyloid Pathology in a New Homozygous Mouse Model of Alzheimer´s Disease”. PLoS ONE 4(11): e7931